J&J’s Doxil Cancer Drug Faces 12-Month Holdup

Johnson & Johnson (J&J) doesn’t expect to receive new supplies of its cancer drug Doxil from a troubled contract manufacturer’s plant until late 2012, at the earliest. J&J will pursue other options to bring Doxil back to patients, including shifting production to another supplier, spokeswoman Lisa Vaga said.
The Wall Street Journal